Skip to main content
Cyxone AB logo

Cyxone AB — Investor Relations & Filings

Ticker · CYXO ISIN · SE0007815428 LEI · 54930034OH16ROAY4K87 ST Professional, scientific and technical activities
Filings indexed 0 across all filing types
Latest filing no filings yet
Country SE Sweden
Listing ST CYXO

About Cyxone AB

https://www.cyxone.com/

Cyxone AB is a clinical-stage biotechnology company focused on developing disease-modifying therapies for autoimmune and autoinflammatory diseases. The company's portfolio includes two primary drug candidates in clinical development. Rabeximod is an immunomodulating agent being investigated for the treatment of rheumatoid arthritis. T20K is a drug candidate for multiple sclerosis, developed using the company's cyclotide technology platform, which is based on stable, plant-derived peptides. Cyxone aims to develop therapies that can significantly improve the quality of life for patients with these chronic conditions.

Recent filings

No filings indexed yet

We are still gathering filings for Cyxone AB. .

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.